Canada’s Drug Agency | Drugs, Health Technologies and Systems.
Canada’s Drug Agency | Drugs, Health Technologies and Systems.

asciminib

Details

Generic Name:
asciminib
Project Status:
Pending
Therapeutic Area:
Philadelphia chromosome-positive chronic myeloid leukemia
Manufacturer:
Novartis Pharmaceuticals Canada
Call for patient/clinician input open:
Brand Name:
Scemblix
Project Line:
Reimbursement Review
Project Number:
PC0405-000
Call for patient/clinician input closed:
Tumour Type:
Leukemia
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
​For the treatment of adult patients with newly diagnosed or previously treated Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
For the treatment of adult patients with newly diagnosed or previously treated Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : January 30, 2025